Tyrosine Kinase Inhibitors in Clinical Practice: Case Reports

The case studies reported in this paper confirm the effectiveness of sunitinib for the treatment of patients with mRCC stratified into different risk groups, with manageable adverse events. There is a need for additional stratification tools and new definitions for tumor responses for the new targeted therapies.